Pelvic cellulitis caused by Raoultella planticola in a neutropenic patient
Al-Sawaf, O., Garcia-Borrega, J., Vehreschild, J.J., Thelen, P., Fätkenheuer, G., Shimabukuro-Vornhagen, A., Kochanek, M., Böll, B.
Published in Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy (01.04.2019)
Published in Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy (01.04.2019)
Get full text
Journal Article
S148: VENETOCLAX‐OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 5‐YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY
Al‐Sawaf, O., Zhang, C., Robrecht, S., Kotak, A., Chang, N., Fink, A.‐M., Tausch, E., Schneider, C., Ritgen, M., Kreuzer, K.‐A., Chyla, B., Eichhorst, B., Jiang, Y., Stilgenbauer, S., Hallek, M., Fischer, K.
Published in HemaSphere (01.06.2022)
Published in HemaSphere (01.06.2022)
Get full text
Journal Article
P641: RETREATMENT WITH VENETOCLAX AFTER VENETOCLAX, OBINUTUZUMAB +/‐ IBRUTINIB: POOLED ANALYSIS OF 13 PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATED IN GCLLSG TRIALS
Cramer, P., Fürstenau, M., Giza, A., Robrecht, S., Tausch, E., Schneider, C., Wendtner, C.‐M., Hoechstetter, M., Schetelig, J., Böttcher, S., Dreger, P., Fink, A.‐M., Langerbeins, P., Al‐Sawaf, O., Fischer, K., Stilgenbauer, S., Eichhorst, B., Hallek, M.
Published in HemaSphere (01.06.2022)
Published in HemaSphere (01.06.2022)
Get full text
Journal Article
S143: TRANSCRIPTOMIC CHARACTERIZATION OF MRD RESPONSE AND NON‐RESPONSE IN PATIENTS TREATED WITH FIXED‐DURATION VENETOCLAX‐OBINUTUZUMAB
Al‐Sawaf, O., Jin, H. Y., Zhang, C., Choi, Y., Balasubramanian, S., Robrecht, S., Kotak, A., Chang, N., Fink, A.‐M., Tausch, E., Schneider, C., Ritgen, M., Kreuzer, K.‐A., Chyla, B., Paulson, J., Eichhorst, B., Stilgenbauer, S., Jiang, Y., Hallek, M., Fischer, K.
Published in HemaSphere (01.06.2022)
Published in HemaSphere (01.06.2022)
Get full text
Journal Article
Richter transformation in chronic lymphocytic leukemia (CLL)—a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials
Al-Sawaf, O., Robrecht, S., Bahlo, J., Fink, A. M., Cramer, P., v Tresckow, J., Lange, E., Kiehl, M., Dreyling, M., Ritgen, M., Dürig, J., Tausch, E., Schneider, C., Stilgenbauer, S., Wendtner, C. M., Fischer, K., Goede, Hallek, M., Eichhorst, B.
Published in Leukemia (01.01.2021)
Published in Leukemia (01.01.2021)
Get full text
Journal Article
MATCHING‐ADJUSTED INDIRECT COMPARISON OF PIRTOBRUTINIB VS VENETOCLAX CONTINUOUS MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CLL TREATED WITH COVALENT BTK INHIBITOR
Eyre, T. A., Al‐Sawaf, O., Jen, M., Hess, L. M., Zhang, J., Goebel, B., Pagel, J. M.
Published in Hematological oncology (01.06.2023)
Published in Hematological oncology (01.06.2023)
Get full text
Journal Article
Management of an adult patient with sickle cell disease and acute chest syndrome by veno-venous extracorporeal membrane oxygenation
Al-Sawaf, O., Köhler, P., Eichenauer, D. A., Böll, B., Kochanek, M., Shimabukuro-Vornhagen, A.
Published in Annals of hematology (01.03.2019)
Published in Annals of hematology (01.03.2019)
Get full text
Journal Article
Deep learning can predict presence of TP53 aberrations and IGHV mutational status from peripheral blood smears of chronic lymphocytic leukemia
Pachong, S. Mebwe, Robrecht, S., Ligtvoet, R., Tausch, E., Schneider, C., Fürstenau, M., Tresckow, J., Huber, H., Stilgenbauer, S., Cramer, P., Eichhorst, B., Kreuzer, K., Hallek, M., Fischer, K., Al‐Sawaf, O.
Published in Hematological oncology (01.06.2023)
Published in Hematological oncology (01.06.2023)
Get full text
Journal Article
VENETOCLAX‐OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6‐YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY
Al‐Sawaf, O., Robrecht, S., Zhang, C., Olivieri, S., Chang, Y. M., Fink, A. M., Tausch, E., Schneider, C., Ritgen, M., Kreuzer, K., Sivcheva, L., Niemann, C., Schwarer, A., Loscertales, J., Weinkove, R., Strumberg, D., Kilfoyle, A., Runkel, E. D., Eichhorst, B., Stilgenbauer, S., Jiang, Y., Hallek, M., Fischer, K.
Published in Hematological oncology (01.06.2023)
Published in Hematological oncology (01.06.2023)
Get full text
Journal Article
IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT‐NAïVE EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF THE CLL12 TRIAL
Langerbeins, P., Robrecht, S., Nieper, P., Cramer, P., Fürstenau, M., Al‐Sawaf, O., Fink, A., Kreuzer, K., Vehling‐Kaiser, U., Tausch, E., Schneider, C., Müller, L., Schlag, R., Freier, W., Gaska, T., Balser, C., Reiser, M., Stauch, M., Zahn, M., Dörfel, S., Eckart, M. J., Staib, P., Behlendorf, T., Hensel, M., Hebarth, H., Klaproth, H., Block, A., Liersch, R., Hauch, U., Heinrich, B., Wendtner, C., Fischer, K., Stilgenbauer, S., Eichhorst, B., Hallek, M.
Published in Hematological oncology (01.06.2023)
Published in Hematological oncology (01.06.2023)
Get full text
Journal Article
BENDAMUSTINE, FOLLOWED BY OBINUTUZUMAB, ACALABRUTINIB AND VENETOCLAX IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): CLL2‐BAAG TRIAL OF THE GCLLSG
Cramer, P, Fürstenau, M, Robrecht, S, Giza, A, Fink, A. M, Fischer, K, Langerbeins, P, Al Sawaf, O, Tausch, E, Schneider, C, Schetelig, J, Dreger, P, Böttcher, S, Kreuzer, K. A, Schilhabel, A, Brüggemann, M, Kneba, M, Wendtner, C. M, Stilgenbauer, S, Eichhorst, B, Hallek, M
Published in Hematological oncology (01.06.2021)
Published in Hematological oncology (01.06.2021)
Get full text
Journal Article
VENETOCLAX‐OBINUTUZUMAB MODULATES CLONAL GROWTH: RESULTS OF A POPULATION‐BASED MINIMAL RESIDUAL DISEASE MODEL FROM THE RANDOMIZED CLL14 STUDY
Al‐Sawaf, O, Zhang, C, Lu, T, Liao, M. Z, Panchal, A, Robrecht, S, Ching, T, Tandon, M, Fink, A.‐M, Tausch, E, Ritgen, M, Böttcher, S, Kreuzer, K.‐A, Kim, S, Miles, D, Wendtner, C, Stilgenbauer, S, Eichhorst, B, Jiang, Y, Hallek, M, Fischer, K
Published in Hematological oncology (01.06.2021)
Published in Hematological oncology (01.06.2021)
Get full text
Journal Article
GENETIC MARKERS AND OUTCOME WITH FRONT LINE OBINUTUZUMAB PLUS EITHER CHLORAMBUCIL OR VENETOCLAX ‐ UPDATED ANALYSIS OF THE CLL14 TRIAL
Tausch, E, Schneider, C, Yosifov, D, Robrecht, S, Zhang, C, Al‐Sawaf, O, Eichhorst, B, Fink, A.‐M, Bloehdorn, J, Kreuzer, K.‐A, Tandon, M, Jiang, Y, Kim, S. Y, Porro Lura, M, Döhner, H, Fischer, K, Hallek, M, Stilgenbauer, S
Published in Hematological oncology (01.06.2021)
Published in Hematological oncology (01.06.2021)
Get full text
Journal Article
A CONTINUOUS INDIVIDUALIZED RISK INDEX FOR REFINED OUTCOME PREDICTION AFTER TARGETED THERAPY FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CIRI‐CLL)
Al‐Sawaf, O., Esfahani, M. S., Zhang, C., Tausch, E., Schilhabel, A., Eichhorst, B., Stilgenbauer, S., Hallek, M., Alizadeh, A. A., Kurtz, D. M., Fischer, K.
Published in Hematological oncology (01.06.2021)
Published in Hematological oncology (01.06.2021)
Get full text
Journal Article
MATCHING-ADJUSTED INDIRECT COMPARISON OF PIRTOBRUTINIB VS VENETOCLAX CONTINUOUS MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CLL PREVIOUSLY TREATED WITH A COVALENT BTK INHIBITOR
Al-Sawaf, O, Jen, M, Hess, LM, Zhang, J, Goebel, B, Pagel, JM, Eyre, TA, Presenter, LYCGN
Published in Hematology, Transfusion and Cell Therapy (01.10.2023)
Published in Hematology, Transfusion and Cell Therapy (01.10.2023)
Get full text
Journal Article
Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis by the German CLL study group
Al-Sawaf, O, Robrecht, S, Bahlo, J, Fink, A M, Cramer, P, von Tresckow, J, Maurer, C, Bergmann, M, Seiler, T, Lange, E, Kneba, M, Stilgenbauer, S, Döhner, H, Kiehl, M G, Jäger, U, Wendtner, C M, Fischer, K, Goede, V, Hallek, M, Eichhorst, B, Hopfinger, G
Published in Leukemia (01.10.2017)
Published in Leukemia (01.10.2017)
Get full text
Journal Article
THE CLL‐RT1 TRIAL: A MULTICENTER PHASE‐2 TRIAL OF ZANUBRUTINIB, A BTK INHIBITOR, PLUS TISLELIZUMAB, A PD‐1 INHIBITOR, FOR PATIENTS WITH RICHTER TRANSFORMATION
Al‐Sawaf, O., Robrecht, S., Stumpf, J., Fink, A.‐M., Ritgen, M., Johansson, P., Tausch, E., Hoechstetter, M., Staber, P., Jäger, U., Niemann, C. U., Pallasch, C., Kreuzer, K.‐A., Stilgenbauer, S., Fischer, K., Wendtner, C., Hallek, M., Eichhorst, B.
Published in Hematological oncology (01.06.2021)
Published in Hematological oncology (01.06.2021)
Get full text
Journal Article
VENETOCLAX‐OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 4‐YEAR FOLLOW‐UP ANALYSIS OF THE RANDOMIZED CLL14 STUDY
Al‐Sawaf, O., Zhang, C., Robrecht, S., Tandon, M., Panchal, A., Fink, A.‐M., Tausch, E., Ritgen, M., Kreuzer, K.‐A., Kim, S., Wendtner, C., Eichhorst, B., Stilgenbauer, S., Jiang, Y., Hallek, M., Fischer, K.
Published in Hematological oncology (01.06.2021)
Published in Hematological oncology (01.06.2021)
Get full text
Journal Article
HIGH EFFICACY OF VENETOCLAX PLUS OBINUTUZUMAB IN PATIENTS WITH COMPLEX KARYOTYPE (CKT) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A PROSPECTIVE ANALYSIS FROM THE CLL14 TRIAL
Al‐Sawaf, O., Lilienweiss, E., Bahlo, J., Robrecht, S., Fink, A., Patz, M., Tandon, M., Humphrey, K., Jiang, Y., Schary, W., Porro Lurà, M., Ritgen, M., Tausch, E., Stilgenbauer, S., Eichhorst, B., Fischer, K., Hallek, M., Kreuzer, K.
Published in Hematological oncology (01.06.2019)
Published in Hematological oncology (01.06.2019)
Get full text
Journal Article
IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT‐NAÏVE EARLY STAGE CLL: PRIMARY ENDPOINT RESULTS OF THE PHASE 3 DOUBLE‐BLIND RANDOMIZED CLL12 TRIAL
Langerbeins, P., Bahlo, J., Rhein, C., Gerwin, H., Cramer, P., Fürstenau, M., Al‐Sawaf, O., Tresckow, J., Fink, A.M., Kreuzer, K., Vehling‐Kaiser, U., Tausch, E., Müller, L., Eckart, M., Schlag, R., Freier, W., Gaska, T., Balser, C., Reiser, M., Stauch, M., Wendtner, C., Fischer, K., Stilgenbauer, S., Eichhorst, B., Hallek, M.
Published in Hematological oncology (01.06.2019)
Published in Hematological oncology (01.06.2019)
Get full text
Journal Article